Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.31 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28979 | 0.81 | HTR2A (0.49) | MAPTHTR2AHTR2C | |
| SCHEMBL413823 | 0.79 | HTR2A (0.50) | HTR2AHTR2C | |
| SCHEMBL850727 | 0.79 | HTR2C (0.50) | MAPTHTR2AHTR2C | |
| SCHEMBL2502244 | 0.79 | KDM4E (0.36) | MAPTHTR2AHTR2C | |
| SCHEMBL30967900 | 0.79 | HTR2A (0.50) | HTR2AHTR2C | |
| SCHEMBL30949143 | 0.79 | HTR2A (0.50) | MAPTHTR2AHTR2C | |
| SCHEMBL2073701 | 0.79 | PRKCI (0.53) | MAPTHTR2AHTR2CPRKCI | |
| SCHEMBL29119 | 0.77 | HTR2C (0.54) | MAPTHTR2C | |
| SCHEMBL30711626 | 0.76 | HTR2C (0.35) | HTR2AHTR2CPRKCI | |
| SCHEMBL7325942 | 0.76 | CA1 (0.37) | PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507469-B2 | Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137280-A1 | AZETIDIN COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR | HTR6, HTR4, HTR3C | MAPT 4616/4885HTR2A 18/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.